Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab in Severe Hemophilia A Following Emicizumab Discontinuation
NCT06703606Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of marstacimab in hemophilia A, sponsored by Pfizer. Primary endpoints: Incidence of marstacimab-related adverse events at 178 days and Incidence of marstacimab-related serious adverse events at 178 days. Started May 2025; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06703606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703606.